About: Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre's experience

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre's experience Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 03 July 2013

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) bài báo khoa học (vi) article scientifique (fr) artículu científicu espublizáu en 2013 (ast) наукова стаття, опублікована в липні 2013 (uk) scientific article published on 03 July 2013 (en) مقالة علمية نشرت في 03 يوليو 2013 (ar)
publication date	wds:Q37362983-EF6E5B9E-EB9E-4827-B981-2C040156F21F
publication date	2013-07-03 00:00:00Z (xsd:dateTime)
cites work	wds:Q37362983-0A61AA8C-9F41-45A3-8D70-EF8A3A652C4F wds:Q37362983-186648A7-34D1-4C5B-8383-B837E8EEB737 wds:Q37362983-2AEA22AB-DC03-4C73-AD34-C7DE17AF64B9 wds:Q37362983-2C70BC84-B915-4D76-88C7-F0B43F94FF2D wds:Q37362983-362F7666-A6EF-4EF3-8467-C363E1B51F95 wds:Q37362983-6C3724E0-8FA6-4A1B-8240-33475251DD1A wds:Q37362983-75DEBFF3-3DBA-41B2-AC68-51B81A514218 wds:Q37362983-A1E61A8B-49BA-47AB-86F9-F7C47B0C59F0 wds:Q37362983-EBE31C6F-0517-4F10-B2EB-6222806E41BF wds:Q37362983-FD1C0986-72B0-4DEC-883C-AA338C1551BD
cites work	Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. The effect of prior exposure to imatinib on transplant-related mortality. Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS) Donor lymphocyte infusions: the long and winding road: how should it be traveled? Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation Management of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia Role of allo-SCT for CML in 2010.
author name string	wds:Q37362983-08A4488A-825A-46EE-9FE3-D42EE8F68267 wds:Q37362983-0B21C258-8E2B-4E01-8251-8AAC657A200B wds:Q37362983-49B7891E-04E7-4122-B11F-08108DA680AF
author name string	Andrew Clark Grant McQuaker Anne-Louise Latif
rdfs:label	Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre's experience (en) Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre's experience (nl) Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre's experience (ast)
skos:prefLabel	Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre's experience (en) Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre's experience (nl) Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre's experience (ast)
name	Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre's experience (en) Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre's experience (nl) Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre's experience (ast)
author	wds:Q37362983-08104EEB-6596-4047-8311-4074B8565CC2 wds:Q37362983-C2CD77C5-FA3B-40A1-A006-BB423E8963F6
author	Anne Parker Mhairi Copland
title	wds:Q37362983-592EF15A-7E5B-4610-B8FA-56DF82E1633F
title	Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre's experience (en)
page(s)	wds:Q37362983-CC64C8A3-29DE-4CD9-B121-EFC8DA78BC6C
page(s)	47-50
instance of	wds:Q37362983-866F1AE2-1426-4B95-97CB-83098C8FD105
instance of	scholarly article
main subject	wds:Q37362983-968FBD6B-B9FB-474D-B69C-47EEF5486288 wds:Q37362983-E4CE28D1-FB6C-4356-87BF-447D664BF02E
main subject	leukemia stem cell transplantation
PubMed ID	wds:Q37362983-A027FE3F-813F-4678-8706-F6954E7A3951
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/24371779
PubMed ID	24371779
published in	wds:Q37362983-B662082C-FEE9-42F4-9830-9843F10E4956
published in	Leukemia research reports
issue	wds:Q37362983-E084032F-CFE2-4EA6-B1EF-35C61FF8AA42
volume	wds:Q37362983-725DDE0C-16E1-41D7-A40A-574AEAAEAFBA
issue	2
volume	2
DOI	wds:Q37362983-C8B2EA30-7C7A-4D1E-9348-727A27DDFCD1
DOI	http://dx.doi.org/10.1016/J.LRR.2013.05.001
DOI	10.1016/J.LRR.2013.05.001
Fatcat ID	wds:Q37362983-A45900EA-B7D3-46BA-BE74-2150567B1A80
Fatcat ID	release_24cpycnso5csrgfqpn24gydw6q
ResearchGate publication ID	wds:Q37362983-21BA11D2-736F-45C5-84BE-06F61E1AC793
ResearchGate publication ID	259172761
PMCID	wds:Q37362983-FECD08F0-57D9-4EA7-A7B5-589473972A85
PMCID	3850380
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q37362983
is cites work of	Accelerated Phase CML: Outcomes in Newly Diagnosed vs. Progression From Chronic Phase
is cites work of	wds:Q38757051-84287C03-0E59-4855-8F76-26C2C93DF9B7

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software